Victoria E R Parker
AstraZeneca (United Kingdom)(GB)AstraZeneca (South Korea)(KR)AstraZeneca (Poland)(PL)AstraZeneca (Germany)(DE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Diabetes Management and Research, Vascular Malformations and Hemangiomas, Genetic and rare skin diseases.
Most-Cited Works
- → Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA(2012)317 cited
- → Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrum(2014)305 cited
- → MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study(2018)295 cited
- → Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist(2019)116 cited
- → Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation(2016)64 cited
- → Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy(2018)63 cited